Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

2019178 citationsJournal Articlehybrid Open Access

Authors

Semaglutide significantly reduced ALT and hsCRP in clinical trials in subjects with obesity and/or type 2 diabetes.

Good health and well-being

Published in: Alimentary Pharmacology & Therapeutics

Volume 50, Issue 2, pp. 193-203

Field-Weighted Citation Impact: 14.51